Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Leukemia ; 30(10): 2019-2025, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27133817

RESUMO

This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter's transformations (RTs) following first-line treatment of chronic lymphocytic leukemia within four phase II/III trials of the GCLLSG evaluating fludarabine (F) vs F+cyclophosphamide (FC), chlorambucil vs F, FC without or with rituximab, and bendamustine+R (BR). Among 1458 patients, 239 (16.4%) experienced either an SPM (N=191) or a RT (N=75). Solid tumors (N=115; 43.2% of all second neoplasias) appeared most frequently, followed by RTs (N=75; 28.2%). Patients showed a 1.23-fold increased risk of solid tumors in comparison to the age-matched general population from the German cancer registry. Age>65 (hazard ratio (HR) 2.1; P<0.001), male sex (HR 1.7; P=0.01), co-morbidities (HR 1.6; P=0.01) and number of subsequent treatments⩾1 (HR 12.1; P<0.001) showed an independent adverse prognostic impact on SPM-free survival. Serum thymidine kinase>10 U/l at trial enrollment (HR 3.9; P=0.02), non-response to first-line treatment (HR 3.6; P<0.001) and number of subsequent treatments⩾1 (HR 30.2; P<0.001) were independently associated with increased risk for RT.


Assuntos
Transformação Celular Neoplásica/induzido quimicamente , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Segunda Neoplasia Primária/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Cloridrato de Bendamustina/administração & dosagem , Cloridrato de Bendamustina/uso terapêutico , Estudos de Casos e Controles , Clorambucila/administração & dosagem , Clorambucila/uso terapêutico , Ciclofosfamida/administração & dosagem , Ciclofosfamida/uso terapêutico , Intervalo Livre de Doença , Feminino , Alemanha , Humanos , Leucemia Linfocítica Crônica de Células B/mortalidade , Masculino , Pessoa de Meia-Idade , Segunda Neoplasia Primária/mortalidade , Sistema de Registros , Medição de Risco , Fatores de Risco , Vidarabina/administração & dosagem , Vidarabina/análogos & derivados , Vidarabina/uso terapêutico
2.
Ann Hematol ; 94(10): 1717-25, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26259502

RESUMO

Allogeneic stem cell transplantation is a treatment option for patients with poor risk CLL. We conducted a retrospective analysis of all CLL patients allografted at our institution, the University Hospital of Cologne, Germany. Data was collected on 40 patients from 2004 to 2012. The mean age was 54, and the majority were male (75 %). On average, the patients were diagnosed 6 years (range 2-12) prior to transplant with an average of 4 years (range 1-8) from time of first-line therapy to transplant. The remission states at the time of transplant were complete remission (CR) (n = 4), stable disease (n = 10), partial remission (n = 20) and progressive disease (n = 6). Only reduced intensity conditioning regimens were employed. The average CD34(+) cell dose was 4.16 × 10(6)/kg. Neutrophil engraftment was seen by day +17 (range 10-23) post-transplant, and 88 % achieved 95-100 % donor chimerism by day 100. Overall survival, progression-free survival and non-relapse mortality at 2 years post-transplant were 65, 52.5 and 27.5 %, respectively. A total of 51 % of patients were found to be minimal residual disease (MRD)-negative at 1 year post-transplant. Our single-centre experience confirms the valuable role of allogeneic stem cell transplantation (allo-SCT) in the treatment of poor risk CLL patients with promising long-term survival and acceptable transplant-related mortality. The advent of newer therapeutic agents should not hinder the consideration of allo-SCT for this patient cohort as it remains the only curative option for these patients.


Assuntos
Transplante de Células-Tronco Hematopoéticas/mortalidade , Leucemia Linfocítica Crônica de Células B/mortalidade , Leucemia Linfocítica Crônica de Células B/terapia , Adulto , Idoso , Feminino , Transplante de Células-Tronco Hematopoéticas/tendências , Humanos , Leucemia Linfocítica Crônica de Células B/diagnóstico , Masculino , Pessoa de Meia-Idade , Morbidade , Mortalidade/tendências , Estudos Retrospectivos , Transplante Homólogo/mortalidade , Transplante Homólogo/tendências , Resultado do Tratamento
3.
Dtsch Med Wochenschr ; 138(13): 655-7, 2013 Mar.
Artigo em Alemão | MEDLINE | ID: mdl-23512367

RESUMO

Morbidity and mortality (M&M) conferences serve as a forum for the discussion of adverse events and errors in the treatment of patients. In the United States M&M conferences are an established part of medical training programs. While being state of the art in specialities like surgery and anesthesiology, they were established later on in internal medicine. To date, no reports have been published on M&M conferences in departments of internal medicine in Germany. Since August 2010 a morbidity and mortality conference takes place once per month in the Department I of Internal Medicine of the university hospital of Cologne. Cases with unexpected death, unexpected complications or medical errors are discussed. The primary goal is to create an open and confidential forum for doctors, where errors can be discussed without any assignment of guilt. The uncovering of structural problems frequently leads to direct improvements in patient care. Furthermore, the conference can play an important role in medical education.


Assuntos
Congressos como Assunto , Educação Médica Continuada , Educação de Pós-Graduação em Medicina , Mortalidade Hospitalar , Medicina Interna/educação , Medicina Interna/normas , Erros Médicos , Morbidade , Alemanha , Humanos , Controle de Qualidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...